$0.73
+0.01 (+0.90%)
Open$0.75
Previous Close$0.72
Day High$0.75
Day Low$0.73
52W High$3.15
52W Low$0.68
Volume—
Avg Volume24.0K
Market Cap31.18M
P/E Ratio—
EPS$-0.35
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,962.6% upside
Current
$0.73
$0.73
Target
$15.08
$15.08
$11.92
$15.08 avg
$19.61
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.42M | 17.19M | 14.45M |
| Net Income | 959.9K | 1.03M | 875.1K |
| Profit Margin | 5.2% | 6.0% | 6.1% |
| EBITDA | 1.74M | 1.49M | 1.43M |
| Free Cash Flow | 993.5K | 1.08M | 606.8K |
| Rev Growth | +1.0% | +13.6% | +14.7% |
| Debt/Equity | 0.15 | 0.16 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |